Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study

2004 ◽  
Vol 42 (02) ◽  
pp. 98-102 ◽  
Author(s):  
D. Anderson ◽  
N. Kato ◽  
K. Onomichi ◽  
H. Uchida ◽  
S. Shelley ◽  
...  
Keyword(s):  
High Dose ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Dose Aspirin ◽  
High Dose Aspirin

Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study

2011 ◽  
Vol 38 (10) ◽  
pp. 2186-2192 ◽  
Author(s):  
YOSHIAKI FURUYA ◽  
MASATAKA KUWANA
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Pulmonary Function ◽  
Lung Disease ◽  
Pulmonary Function Tests ◽  
High Dose ◽  
Open Label ◽  
High Resolution Computed Tomography ◽  
Open Label Study ◽  
Label Study

Objective.To evaluate the clinical benefits of the endothelin receptor antagonist bosentan on interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) who are ineligible for cyclophosphamide (CYC) therapy.Methods.In this prospective open-label study, 9 patients with SSc and ILD received bosentan for 24 months. The main reasons for avoiding CYC included severely impaired lung function, long disease duration, and relapse after CYC treatment. Pulmonary function tests and Doppler echocardiograms were evaluated every 6 months, and high-resolution computed tomography (HRCT) was performed every 12 months. For an extended survival analysis, 17 historical controls who met the inclusion criteria at referral and had not used any immunosuppressive or antifibrotic agents thereafter were selected from the SSc database.Results.Two patients did not finish the study; one developed vasculitis requiring high-dose corticosteroids and another died of bacterial pneumonia. The remaining 7 patients tolerated bosentan and completed the study period. There were trends toward mildly reduced forced vital capacity, total lung capacity, and diffusing capacity for carbon monoxide over time. Two patients developed pulmonary hypertension during the 24-month period. HRCT scores for ground-glass opacity, pulmonary fibrosis, and honeycomb cysts gradually increased. In the extended study, there was no difference in cumulative survival rate between the bosentan-treated and historical control groups.Conclusion.The gradual worsening of pulmonary function and HRCT findings in patients treated with bosentan was consistent with the natural course of SSc-associated ILD. This study does not support the use of bosentan for SSc-associated ILD even when CYC treatment is inadvisable.

An Open-Label Study of the Therapeutic Efficacy of High-Dose Famotidine Adjuvant Pharmacotherapy in Schizophrenia: Preliminary Evidence for Treatment Efficacy

1996 ◽  
Vol 19 (4) ◽  
pp. 341-348 ◽  
Author(s):  
Richard B. Rosse ◽  
Kathie Kendrick ◽  
Maureen Fay-McCarthy ◽  
George D. Prell ◽  
Paul Rosenberg ◽  
...  
Keyword(s):  
Treatment Efficacy ◽  
Therapeutic Efficacy ◽  
Preliminary Evidence ◽  
High Dose ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia

1995 ◽  
Vol 15 (1-2) ◽  
pp. 148
Author(s):  
Richard B. Rosse ◽  
Kathleen A. Kendrick ◽  
Maureen Fay-McCarthy ◽  
Joseph P. Collins ◽  
Paul B. Rosenberg ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
High Dose ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Low and high dose aripiprazole augmentation in major depressive disorder: a randomised, open-label study

2017 ◽  
Vol 27 ◽  
pp. S861 ◽  
Author(s):  
S.H. Horikoshi ◽  
I.M. Miura ◽  
S.Y. Yamamoto ◽  
O.A. Abe ◽  
M.I. Ito ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
High Dose ◽  
Open Label ◽  
Major Depressive ◽  
Open Label Study ◽  
Label Study

P.2.e.022 Effectiveness and safety of amisulpride's high dose in acute mania: an open label study

2009 ◽  
Vol 19 ◽  
pp. S461
Author(s):  
S. Arques ◽  
M.A. Pino ◽  
D. Villavicencio ◽  
P. Sierra ◽  
L. Livianos
Keyword(s):  
Acute Mania ◽  
High Dose ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study

2011 ◽  
Vol 26 (2) ◽  
pp. 125-132 ◽  
Author(s):  
Gihyun Yoon ◽  
Suck Won Kim ◽  
Paul Thuras ◽  
Joseph Westermeyer
Keyword(s):  
Alcohol Dependence ◽  
High Dose ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document